Author Archives: admin


Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25

COPENHAGEN, Denmark, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will hold a conference call and live webcast on Wednesday, August 25, 2021 at 4:30 p.m. Eastern Time (ET) to review its second quarter 2021 financial results and provide a business update.

Go here to see the original:
Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25

FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

SAN DIEGO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that the U.S. Food and Drug Administration (FDA) approved a second indication for GSK’s JEMPERLI (dostarlimab-gxly) for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.

See the article here:
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer

TORONTO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that Revive has entered into an exclusive license agreement (the “Agreement”) with Puerto Rico Science Technology and Research Trust (“PRSTRT”), representing Universidad Central del Caribe (“UCC”) and St. Jude Children’s Research Hospital (“St. Jude”), for the intellectual property (International Patent Application No. PCT/US2020/017053/) titled, Biologically Active Ganoderma Lucidum Compounds and Synthesis of Anticancer Derivatives; Ergosterol Peroxide Probes for Cellular Localization. Researchers at St. Jude and UCC have characterized medicinal mushroom Ganoderma lucidum compounds with anti-cancer activity, specifically signi?cant activity against breast cancer, thus having the potential to treat the most aggressive types of breast cancers such as triple negative breast cancer and in?ammatory breast cancer.

See the rest here:
Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer

Chalice Brands Ltd. Announces Timing of Its Second Quarter Earnings Results

PORTLAND, Ore., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Chalice Brands Ltd. (CSE:CHAL) (OTCQB:CHALF) (“Chalice” or the “Company”), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, today announces it will report its second quarter 2021 results on Thursday, August 26, 2021 after market close.

Continue reading here:
Chalice Brands Ltd. Announces Timing of Its Second Quarter Earnings Results

Telix and Merck KGaA, Darmstadt, Germany, to Commence Pan-Cancer Clinical Combination Studies

MELBOURNE, Australia, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has entered into a pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany, to conduct combination studies with one of Merck KGaA, Darmstadt, Germany’s investigational proprietary DNA Damage Response Inhibitor (DDRi) molecules in combination with each of Telix’s TLX591 (177Lu-rosopatamab) and TLX250 (177Lu-girentuximab) molecularly targeted radiation (MTR) therapeutic programs. This clinical collaboration builds on the success of a strategic research collaboration agreement between Telix and Merck KGaA, Darmstadt, Germany announced in August 2019.1

Here is the original post:
Telix and Merck KGaA, Darmstadt, Germany, to Commence Pan-Cancer Clinical Combination Studies

Telix and Merck to Commence Pan-Cancer Clinical Combination Studies

MELBOURNE, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has entered into a pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany (‘Merck’), to conduct combination studies with one of Merck’s investigational proprietary DNA Damage Response Inhibitor (DDRi) molecules in combination with each of Telix’s TLX591 (177Lu-rosopatamab) and TLX250 (177Lu-girentuximab) molecularly targeted radiation (MTR) therapeutic programs. This clinical collaboration builds on the success of a strategic research collaboration agreement between Telix and Merck announced in August 2019.1

See the original post here:
Telix and Merck to Commence Pan-Cancer Clinical Combination Studies

Two New Studies to Explore Telix Assets in Breast Cancer Theranostics

MELBOURNE, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces the initiation of two new investigator-led studies to evaluate the potential utility of the Company’s late-stage imaging portfolio in women’s health, initially in two sub-types of breast cancer with a significant unmet medical need. Both TLX591-CDx and TLX250-CDx have potential utility in breast cancer imaging, particularly for specific phenotypes that are not consistently well imaged using existing techniques.

Read the original here:
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics

Selma Blair Shares That Shes Now in Remission 3 Years After MS Diagnosis – Self

Three years after actor Selma Blair received her multiple sclerosis (MS) diagnosis, her treatment is working well and her prognosis is positive.

"My prognosis is great. I'm in remission. Stem cell put me in remission," Blair said at a TCA panel in support of the upcoming Introducing Selma Blair documentary, per People. "It took about a year after stem cell for the inflammation and lesions to really go down."

Multiple sclerosis is thought to be an autoimmune condition that occurs when the body's immune system begins attacking the protective myelin sheaths that coat and protect nerve fibers. That can cause communication issues along the nerves and, over time, lead to permanent nerve damage.

People who have MS can have a range of symptoms such as fatigue, dizziness, tingling, balance issues, muscle weakness, and changes in vision (like blurred vision or double vision). The symptoms typically come and go, and someone may experience a flare of their symptoms (that can last days, weeks, or months) or they might be in a period of remission when their symptoms wane (but don't necessarily disappear completely).

Although there is no cure for MS, there are a variety of medications and treatment options that can help manage the symptoms. Experts are still researching and developing stem cell therapy for MS, the type of treatment Blair mentioned. To use stem cells to manage more aggressive forms of MS, doctors will typically perform an autologous stem cell transplant, the Mayo Clinic says, meaning they'll take a patient's own stem cells and use them to replenish their bone marrow. This type of stem cell transplant is most commonly used in the treatment of conditions such as myeloma, Hodgin's lymphoma, and non-Hodgkin's lymphoma, the Mayo Clinic says.

Blair was first diagnosed with MS in 2018 after dealing with symptoms like falling, dropping things, chronic pain, and a foggy memory, she revealed in an Instagram post. At first, Blair said she attributed her symptoms to a pinched nerve, but received her diagnosis after undergoing an MRI.

She told the panel that, for the past few months, she's been feeling noticeably better. But she was reluctant to talk about her improvements publicly because she felt like she still needed to be more healed and more fixed, People reports. "I've accrued a lifetime of some baggage in the brain that still needs a little sorting out or accepting. That took me a minute to get to that acceptance. It doesn't look like this for everyone."

In grappling with her diagnosis, Blair has found that being open with how she's feeling and what her life looks like now have been helpfulfor herself and others. "To hear even just me showing up with a cane or sharing something that might be embarrassing, it was a key for a lot of people in finding comfort in themselves and that means everything to me," she said.

Related:

Read the original post:
Selma Blair Shares That Shes Now in Remission 3 Years After MS Diagnosis - Self